Cite
HARVARD Citation
Cameron, D. et al. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 389 (10075), pp. 1195-1205. [Online].